| Dr Troy W Zabel, MD | |
|
950 E Harvard Ave, Suite 240, Denver, CO 80210-7006 | |
| (303) 871-0977 | |
| (303) 733-2387 |
| Full Name | Dr Troy W Zabel |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 25 Years |
| Location | 950 E Harvard Ave, Denver, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962435479 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 40811 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Englewood Dialysis (dva) | Englewood, CO | Dialysis facility |
| Hca-healthone Dba Swedish Medical Center | Englewood, CO | Hospital |
| Littleton Adventist Hospital, Centura Health | Littleton, CO | Hospital |
| Centura Health-porter Adventist Hospital | Denver, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Denver Nephrologists Pc | 8729991393 | 52 |
News Archive
Immune checkpoint inhibitors are a type of cancer treatment that help the immune system's T cells recognize and attack tumors. But these immunotherapy drugs aren't effective against all cancers.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
The National Cancer Institute's Small Business Innovation Research (SBIR) Program has awarded Lpath (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, two Phase 1 grants totaling $0.3 million. This follows a series of other SBIR grants awarded to Lpath totaling $6.9 million, including a $3.0 million Phase 2 bridge grant from the NCI awarded this past June.
Trius Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections, announced today its financial results for the three months ended June 30, 2010.
In a startling new study that involved research on both sides of the Atlantic, scientists from The Scripps Research Institute in Florida and the University College London Institute of Neurology in England have shown for the first time that abnormal prions, bits of infectious protein devoid of DNA or RNA that can cause fatal neurodegenerative disease, can suddenly erupt from healthy brain tissue.
› Verified 5 days ago
| Entity Name | Denver Nephrologists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598877516 PECOS PAC ID: 8729991393 Enrollment ID: O20031110000465 |
News Archive
Immune checkpoint inhibitors are a type of cancer treatment that help the immune system's T cells recognize and attack tumors. But these immunotherapy drugs aren't effective against all cancers.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
The National Cancer Institute's Small Business Innovation Research (SBIR) Program has awarded Lpath (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, two Phase 1 grants totaling $0.3 million. This follows a series of other SBIR grants awarded to Lpath totaling $6.9 million, including a $3.0 million Phase 2 bridge grant from the NCI awarded this past June.
Trius Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections, announced today its financial results for the three months ended June 30, 2010.
In a startling new study that involved research on both sides of the Atlantic, scientists from The Scripps Research Institute in Florida and the University College London Institute of Neurology in England have shown for the first time that abnormal prions, bits of infectious protein devoid of DNA or RNA that can cause fatal neurodegenerative disease, can suddenly erupt from healthy brain tissue.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Troy W Zabel, MD 130 Rampart Way, Ste 300b, Denver, CO 80230-6451 Ph: (303) 327-4700 | Dr Troy W Zabel, MD 950 E Harvard Ave, Suite 240, Denver, CO 80210-7006 Ph: (303) 871-0977 |
News Archive
Immune checkpoint inhibitors are a type of cancer treatment that help the immune system's T cells recognize and attack tumors. But these immunotherapy drugs aren't effective against all cancers.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
The National Cancer Institute's Small Business Innovation Research (SBIR) Program has awarded Lpath (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, two Phase 1 grants totaling $0.3 million. This follows a series of other SBIR grants awarded to Lpath totaling $6.9 million, including a $3.0 million Phase 2 bridge grant from the NCI awarded this past June.
Trius Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections, announced today its financial results for the three months ended June 30, 2010.
In a startling new study that involved research on both sides of the Atlantic, scientists from The Scripps Research Institute in Florida and the University College London Institute of Neurology in England have shown for the first time that abnormal prions, bits of infectious protein devoid of DNA or RNA that can cause fatal neurodegenerative disease, can suddenly erupt from healthy brain tissue.
› Verified 5 days ago
Katrina Wagoner-hursh, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1835 Franklin St, Denver, CO 80218 Phone: 303-338-4545 | |
Emily Martin Jones, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 8111 E Lowry Blvd, Denver, CO 80230 Phone: 720-848-0000 | |
Dr. Jesus Heliodoro Hermosillo Rodriguez, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2045 N Franklin St, Denver, CO 80205 Phone: 303-338-4545 | |
Margaret Hay, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1601 E 19th Ave Ste 3100, Denver, CO 80218 Phone: 303-863-0300 Fax: 303-863-7014 | |
Dr. Alan W Burgess, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1601 E 19th Ave Ste 6000, Denver, CO 80218 Phone: 303-861-7001 Fax: 303-861-8624 | |
Dr. Sahibzada Mohsin Shah, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 777 Bannock St, Denver, CO 80204 Phone: 303-436-6000 | |
Shyam M Parkhie, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 130 Rampart Way, 300b, Denver, CO 80230 Phone: 720-343-1562 Fax: 720-343-1563 |